Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior

Chunyan Wang,1 Chao Sun,2 Xiujuan Wu,1 Ziyan Ding,1 Kangding Liu,1 Jie Cao1 1Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of China; 2Department of Orthopedic Surgery, Orthopedic Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of ChinaCorrespondence: Jie Cao, Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of China, Email [email protected]: Atherosclerosis is characterized by the deposition of lipid within arterial walls, precipitating the initiation and progression of atherosclerotic lesions. Over time, these plaques enlarge and rupture, initiating thrombosis cascades that pose significant risks to patient safety. Conventional therapies, including 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (eg, statins) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, predominantly target lipid reduction while overlooking the intricate microenvironment within atherosclerotic plaque. Statins possess limited lipid-lowering efficacy and may even exhibit insensitivity or intolerance in patients. While PCSK9 inhibitors, as adjuvant therapy, demonstrate potent lipid-lowering effects, they fail to further stabilize vulnerable plaques. In contrast, biomaterials have emerged as pivotal tools for addressing unstable plaques. By restoring endothelial cell (EC) function, inhibiting neutrophil activation, modulating macrophage behavior, and preventing the phenotypic transformation of smooth muscle cells, biomaterials effectively promote plaque regression. This review explores the pathogenesis of atherosclerosis and highlights recent advancements in biomaterial-based therapies for vulnerable plaques, aiming to offer novel insights and solutions to this pressing global health challenge.Keywords: atherosclerotic plaque, biomaterials, lipid metabolism, inflammation, efferocytosis, oxidative stress

Authors

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2026-05-02
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior

Kangding Liu, Ziyan Ding, Chao Sun, Xiujuan Wu et al.
Dove Medical Press (Taylor and Francis Group)
Lipoproteins and Cardiovascular Health
article

Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior

Kangding Liu, Ziyan Ding, Chao Sun, Xiujuan Wu, Chunyan Wang, Jie Cao
article en

Abstract

Chunyan Wang,1 Chao Sun,2 Xiujuan Wu,1 Ziyan Ding,1 Kangding Liu,1 Jie Cao1 1Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of China; 2Department of Orthopedic Surgery, Orthopedic Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of ChinaCorrespondence: Jie Cao, Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin, People’s Republic of China, Email [email protected]: Atherosclerosis is characterized by the deposition of lipid within arterial walls, precipitating the initiation and progression of atherosclerotic lesions. Over time, these plaques enlarge and rupture, initiating thrombosis cascades that pose significant risks to patient safety. Conventional therapies, including 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (eg, statins) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, predominantly target lipid reduction while overlooking the intricate microenvironment within atherosclerotic plaque. Statins possess limited lipid-lowering efficacy and may even exhibit insensitivity or intolerance in patients. While PCSK9 inhibitors, as adjuvant therapy, demonstrate potent lipid-lowering effects, they fail to further stabilize vulnerable plaques. In contrast, biomaterials have emerged as pivotal tools for addressing unstable plaques. By restoring endothelial cell (EC) function, inhibiting neutrophil activation, modulating macrophage behavior, and preventing the phenotypic transformation of smooth muscle cells, biomaterials effectively promote plaque regression. This review explores the pathogenesis of atherosclerosis and highlights recent advancements in biomaterial-based therapies for vulnerable plaques, aiming to offer novel insights and solutions to this pressing global health challenge.Keywords: atherosclerotic plaque, biomaterials, lipid metabolism, inflammation, efferocytosis, oxidative stress

Dove Medical Press (Taylor and Francis Group)
Openalex Percentile: Top 10%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.